Contribute Try STAT+ Today

As a condition of regulatory approval, drug makers are often required to conduct follow-up studies, but sometimes they also voluntarily agree to run still other trials that can yield important information about the safety, effectiveness, and optimal use of new medicines. However, an analysis finds that few such commitments involved new studies and only half were published in peer-review journals.

Specifically, of 110 drugs and biologics that were approved between 2009 and 2012, more than half — or 55.5% — had at least one post-marketing commitment. But only a minority of those post-marketing commitments involved new clinical trials — 33 of 331, or just 10% — as opposed to ongoing studies, according to the analysis that was published in BMC Medicine.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.